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ABSTRACT
The Ahmed glaucoma valve (AGV) is a popular
glaucoma drainage implant used for the control
of intraocular pressure in patients with glau-
coma. While in the past AGV implantation was
reserved for glaucoma patients poorly con-
trolled after one or more filtration procedures,
mounting evidence has recently encouraged its
use as a primary surgery in selected cases. AGV
has been demonstrated to be safe and effective
in reducing intraocular pressure in patients with
primary or secondary refractory glaucoma.
Compared to other glaucoma surgeries, AGV
implantation has shown favorable efficacy and
safety. The aim of this article is to review the
results of studies directly comparing AGV with
other surgical procedures in patients with
glaucoma.
Keywords: Ahmed glaucoma valve; Glaucoma
drainage implants; Glaucoma tubes; Glaucoma
surgery; Ophthalmology; Trabeculectomy
INTRODUCTION
Glaucoma drainage implants (GDIs) have
become a valuable tool for the surgical man-
agement of refractory glaucoma [1, 2]. GDIs
have been demonstrated to be effective in
reducing intraocular pressure (IOP) and are
especially indicated in cases with high risk of
failure after filtering procedures [3, 4]. Typi-
cally, GDIs are indicated for eyes that have
already undergone one or more glaucoma
surgeries, and for particular types of glaucoma
in which filtering procedures are likely to fail
(e.g., secondary glaucomas) [5–8]. The use of
GDIs as a primary surgical procedure for glau-
coma has also been investigated [9, 10].
Despite some concerns [11], early results are
promising [12].
The Ahmed glaucoma valve (AGV), a GDI
device, was approved by the FDA in 1993 for use
in glaucoma patients with uncontrolled IOP
[13]. Unlike the Molteno and Baerveldt
implants, AGV provides a complex mechanism
to control aqueous humor (AH) flow. Indeed, a
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valve mechanism has been introduced in an
attempt to prevent complications sometimes
encountered with non-valved GDIs, such as
hypotony, shallow anterior chamber, choroidal
effusion and choroidal detachment [14]. Several
studies have shown that AGV is safe and effec-
tive in reducing IOP in patients with primary
[15–17], secondary [18–24] and refractory glau-
coma [25–27]. However, the hypotensive effi-
cacy of AGV in comparison with other
anti-glaucoma interventions has not been
completely elucidated. The aim of the present
review is to describe the results of studies
directly comparing AGV and other IOP-reduc-
ing procedures in patients with glaucoma. This
article is based on previously conducted studies
and does not involve any new studies of human





AGV consists of three parts: (1) a plate which,
depending on the model, is composed of med-
ical grade silicone, polypropylene or poly-
ethylene (Medpor; Porex, Atlanta, GA, USA;
subsequently Stryker, Kalamazoo, MI, USA), (2)
a drainage tube composed of medical grade sil-
icone, and (3) a valve mechanism made of
medical-grade silicone (Fig. 1a). Polypropylene
is a rigid, inflexible plastic, highly resistant to
torsional forces, while silicone is a flexible rub-
ber. Medpor is a porous high-density poly-
ethylene which allows for rapid tissue
integration and vascular ingrowth [28].
The adult model (S2) of AGV provides
184 mm2 of total plate area, while the pediatric
model (S3) provides a total area of 96 mm2.
Obviously, a smaller plate facilitates positioning
in infants and subjects with a small eye. A
variant of the device with two plates (total fil-
tration area: 364 mm2), and one with a clip for
pars plana tube insertion have also been
designed. The recently introduced M4 AGV
model has a total plate area of 160 mm2 not
including the surface area of pores (Table 1).
The valve mechanism of AGV consists of
thin silicone elastomer membranes measuring
8 mm in length and 7 mm in width which cre-
ate a Venturi-type chamber. The membranes are
pre-tensioned to open and close so that, at least
in principle, flow in response to IOP variations
is ensured in the range of 8–12 mmHg [29].
After implantation, AH flows slowly and con-
tinuously into the trapezoidal chamber of the
valve (Fig. 1b). As the pressure reaches the
pre-set threshold value, the valve opens, thus
decreasing the IOP. Since the inlet cross-section
of the chamber is wider than the outlet, a
pressure differential is created across the
chamber. This pressure differential enables the
Fig. 1 Ahmed glaucoma valve. a Ahmed glaucoma valve components; b Ahmed glaucoma valve mechanism
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valve to remain open even with a small pressure
differential between the AC and the subcon-
junctival spaces surrounding the device. In
order for Bernoulli’s equation to be satisfied
(fluid flowing into section A = fluid flowing out
of section B; Fig. 1b), the velocity of the fluid
has to increase as it leaves the chamber through
the drainage tube. This increased velocity and
the non-obtrusive flow account for better evac-
uation and smaller valve friction. The tension of
the silicone membranes helps to reduce the risk
of hypotony by closing the mechanism after the




Ahmed Glaucoma Valve Versus
Trabeculectomy
Trabeculectomy is recognized as the gold-stan-
dard surgery for glaucoma against which other
procedures are evaluated [5, 6, 30]. A compar-
ison between AGV and trabeculectomy may be
biased by the fact that different perceived indi-
cations for each procedure may result in
dissimilar groups being compared. For example,
GDIs are frequently used as a second-line sur-
gery after trabeculectomy has failed. Thus,
when evaluating trials comparing trabeculec-
tomy versus AGV implantation, special atten-
tion should be paid to sample characteristics.
Wilson et al. randomized 117 patients with
primary open angle glaucoma (POAG), primary
angle closure glaucoma (PACG) and secondary
glaucoma to trabeculectomy (n = 62) or AGV
implantation (n = 55) [31]. Totals of 44 of 62
eyes in the trabeculectomy group and 31 of 55
eyes in the AGV group had not undergone any
prior surgical procedure for glaucoma. The
mean follow-up time was 9.7 months, with a
range of 6–13 months. After 1 year, the cumu-
lative probability of success (IOP \21 mmHg
and at least 15% IOP reduction from preopera-
tive level) was 83.6% for the trabeculectomy
group and 88.1% for the AGV group (p = 0.43).
The AGV group required more frequently
adjunctive medical therapy and the trabeculec-
tomy group achieved significantly lower IOP
from week 6 to 15 (12.6 vs. 16.4 mmHg) and
from month 11 to 13 (11.4 vs. 17.2 mmHg).
Long-term results of AGV implantation ver-
sus trabeculectomy as initial surgical manage-
ment in patients with POAG or PACG were later
Table 1 Ahmed glaucoma implants available models
Type Model Surface area (mm2) Material (plate)
Single plate S2 184 Polypropylene
Single plate, pediatric size S3 96 Polypropylene
Double plate B1 364 Polypropylene
Single plate FP7 184 Silicone
Single plate, pediatric size FP8 96 Silicone
Double plate FX1 364 Silicone
Single plate M4 160 Polyethylene
Pars plana PS2 184 Polypropylene
Pars plana, pediatric size PS3 96 Polypropylene
Pars plana PC7 184 Silicone
Pars plana, pediatric size PC8 96 Silicone
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investigated by the same authors [15]. The study
enrolled 123 patients who were followed-up for
31 months. Totals of 64 patients were random-
ized to trabeculectomy and 59 to AGV. In the
first postoperative year, the trabeculectomy
group generally obtained lower pressures, but
differences became statistically significant in
the period between months 11 and 13. Subse-
quently, the IOP in the two groups became
similar through months 41–52, and differences
were not significant except from months 34 to
40, when the AGV group achieved lower pres-
sures. When the authors applied the same cri-
teria of success as in their first study, the
cumulative probability of success was 68.1%
and 69.8% at months 41–52 for the AGV group
and the trabeculectomy group, respectively. No
difference in the rate of complications was
found between the two groups.
Tran et al. compared the efficacy of tra-
beculectomy and AGV in a group of patients
with POAG, exfoliative glaucoma and pigmen-
tary glaucoma [17]. Totals of 61 of 78 patients in
the AGV and 61 of 88 patients in the tra-
beculectomy group had already undergone at
least one procedure for glaucoma. Applying the
same success criteria as in the previous studies
(i.e.: IOP B21 mmHg and at least 15% IOP
reduction from preoperative level), at 5 years
there was no difference in cumulative success
between the groups (36% vs. 48% for the AGV
and the trabeculectomy group, respectively;
p = 0.094). However, when more stringent cri-
teria were used (IOP B18, B15 and B12 mmHg,
and a concomitant IOP reduction C20, C25 and
C30% from baseline), trabeculectomy had sig-
nificantly higher long-term probability of suc-
cess than the AGV implant. The authors
concluded that, when great IOP reduction and
low IOP levels are needed, trabeculectomy
achieves this goal more frequently. Doubts have
been raised about the methodology of this ret-
rospective study and in particular about the
difference in visual acuity and IOP between the
two groups at baseline (which may suggest that
one group had less healthy eyes than the other)
[32].
AGV and trabeculectomy were retrospec-
tively compared by Shen et al. in a sample of 40
eyes with neovascular glaucoma (NVG) [33].
Surgical success was defined as an IOP B21 and
C6 mmHg, with or without medications, and
without the need of further glaucoma surgery.
Only one eye (in the AGV group) had previously
undergone a surgical procedure for glaucoma.
Mean IOP values did not differ between the two
groups at each visit follow-up, although the
trabeculectomy group required a significantly
greater number of medications at months 3 and
6. The respective cumulative success rates for
the AGV and trabeculectomy groups were 90%
and 85% at 6 months, 70% and 65% at
12 months, 60% and 60% at 18 months, and 60
and 55% at 24 months. No significant differ-
ence in the survival curves of the two groups
was found (p = 0.815).
The advent of anti-vascular endothelial
growth factor (anti-VEGF) drugs and their use
as an adjuvant for glaucoma surgery in NVG
has dramatically increased the success of tra-
beculectomy [34–36]. In a prospective inter-
ventional study, Liu et al. randomized 37 eyes
of 36 patients with NVG to AGV implantation
(19 patients) or combined trabeculectomy
with intravitreal ranibizumab injection (18
patients) [37]. The administration of ranibi-
zumab (0.5 mg) was done 1 week before tra-
beculectomy. Complete success was defined as
an IOP C6 and B21 mmHg without any
antiglaucoma medication or further glaucoma
surgery. Partial success was defined as an IOP
\21 mmHg with topical antiglaucoma medi-
cations. In the combined trabeculectomy and
ranibizumab group, 11 eyes (61.1%) achieved
complete success, 6 eyes (33.3%) achieved
partial success and 1 eye (5.6%) failed. In the
AGV group, 11 eyes (57.9%) had complete
success, 2 eyes (10.5%) had partial success,
and 6 eyes (31.6%) failed. Complications were
more common in the AGV group, especially in
the early postoperative period (hypotony,
shallow anterior chamber, hyphema).
Although results from this study are exciting,
additional studies with a larger sample size are
needed to provide clear evidence about the
optimal surgical treatment of NVG. Moreover,
a clinical trial comparing the combination of
AGV with ranibizumab versus the combina-
tion of trabeculectomy with ranibizumab
would be useful.
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Ahmed Glaucoma Valve Versus Ex-Press
Shunts
The Ex-Press Mini Glaucoma Shunt (EXP) is a
biocompatible, non-valved device developed by
Optonol (Neve Ilan, Israel) to control IOP in
glaucoma patients. Initially, EXP was implanted
at the limbus so that the external portion of the
device was only covered by the conjunctiva.
This early technique was associated with a high
rate of complications, including hypotony,
erosion, extrusion and endophthalmitis
[38–42]. To avoid these complications, a modi-
fied guarded technique was adopted, with the
creation of a partial-thickness scleral flap cov-
ering the device at the limbus [43]. EXP was
developed in an effort to make filtration surgery
more straightforward. Nonetheless, it seems
that the efficacy and safety profile of the EXP
are not superior to standard trabeculectomy
[44–47]. Only a few studies directly comparing
AGV and EXP have been published.
Zhang et al. compared the efficacy and safety
of EXP and AGV in a sample of 69 patients with
refractory glaucoma (32 implantedwith EXP and
37 with AGV) [48]. Qualified surgical success was
defined as an IOP C5 mmHg and B21 mmHg,
with or without topical glaucoma medications;
complete surgical success was defined as an IOP
C5 and B21 mmHg without any topical glau-
coma medications. Baseline IOP was
36.6 ± 9.5 mmHg in the EXP group and
35.4 ± 9.1 mmHg in the AGV group. At the
9-month follow-up,patients implantedwithEXP
had qualified and complete success rates of 75%
and 62.5%, respectively, and patients implanted
with AGV had qualified and complete success
rates of 62.1% and 51.3%, respectively (p[0.05).
No difference in postoperative complications
was found between groups. Results from this
study should be interpreted with caution, due to
the short length of follow-up, the race of the
patients (all patients were Asians) and the lack of
information on baseline patient characteristics.
In a recent retrospective study, the efficacy of
EXP and AGV was investigated in 64 eyes of 57
glaucoma patients (EXP implanted in 31 eyes
and AGV in 33 eyes) [49]. At baseline, the AGV
group had higher mean IOP (30.1 ± 10.4 vs.
23.5 ± 7.5 mmHg, p\0.01), more
pseudophakic eyes (72.7% vs. 41.9%, p = 0.02)
and a higher number of previous surgeries,
including trabeculectomy, vitrectomy and ker-
atoplasty (p\0.01). Failure was defined as an
IOP [21 or B5 mmHg on two consecutive
postoperative follow-up visits 3 months from
surgery, reoperation for glaucoma or loss of
light perception. Mean follow-up time was
2.6 ± 1.1 years in the EXP group and
3.3 ± 1.6 years in the AGV group. Failure rates
were 16.1% in patients implanted with EXP and
24.2% in patients implanted with AGV
(p = 0.696). A higher rate of complications was
encountered in the AGV group (60.1%) than in
the EXP group (32.3%). The results of this report
should be interpreted with caution, due to
methodological limitations and baseline differ-
ences between the two study groups.
Further trials directly comparing EXP and
AGV are needed before more confident conclu-
sions can be drawn. However, it is worth noting
that the efficacy of EXP is typically affected by
the same factors that limit the efficacy and
prognosis of other filtration surgeries. Conse-
quently, at least in theory, EXP may be a
less-than-ideal option for secondary glaucomas
at high risk of failure in which aggressive con-
junctival healing and scarring is anticipated.
Ahmed Glaucoma Valve Versus Other
Glaucoma Drainage Implants
Several glaucoma GDIs are currently available.
Their characteristics differ in terms of size,
shape, plate material and presence of a
flow-limiting mechanism. Theoretically, a valve
mechanism embedded in the implant may
reduce postoperative hypotony-related compli-
cations. On the other hand, such a mechanism
could limit AH drainage from the eye so that the
efficacy of the implant would be compromised.
Several comparison studies of AGV versus other
implants have been published.
Ahmed Glaucoma Valve Versus Baerveldt
Implant
Syed et al. retrospectively evaluated the efficacy
of AGV and Baerveldt 350-mm2 implant in
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refractory glaucoma patients (64 eyes, 32
implanted with AGV and 32 with the Baerveldt
device) [50]. Patients were matched for age,
race, gender, glaucoma type, previous ocular
history and preoperative IOP. A ligature with a
7.0 polyglactin suture was performed only in
patients who underwent a Baerveldt implanta-
tion. The suture was tied around the tube
1–2 mm from the plate to limit filtration in the
immediate postoperative period. During the
first year from surgery, both the AGV and the
Baerveldt group had a similar IOP profile. There
was no significant difference in IOP between the
two groups at any visit intervals. Success,
defined as IOP decrease of at least 30% from
baseline and IOP \22 mmHg with or without
medications, was achieved in 25 of the 32
patients (75%) in the Baerveldt group and 24 of
the 32 patients (75%) in the AGV group. The
same rate of complications was recorded for
both devices, with 3 patients (9.4%) in each
group having complications that resulted in
significant loss of vision or necessitated
re-intervention.
Tsai retrospectively compared the efficacy
and safety of AGV and Baerveldt implant in his
personal single-surgeon series. Both med-
ium-term (1 year) [51] and long-term (4 years)
[52] results were reported. Surgical failure was
defined as an IOP[21 or\6 mmHg at the last
post-operative visit, reduction or loss of vision
and additional surgical procedures. Totals of 70
patients underwent Baerveldt implantation
(both 250- and 350-mm2 plate models) and 48
patients underwent AGV implantation. Patients
implanted with the AGV had lower mean IOP
1 day and 1 week (p\0.01) after surgery. After-
ward, no differences were observed in IOP from
1 to 48 months. No significant difference was
found between AGV and Baerveldt implant
survival curves (p C 0.05) up to 48 months of
follow-up. The 1-, 2-, 3- and 4-year survival rates
for AGV and Baerveldt groups were, respec-
tively, 83 and 73% (p = 0.183), and 67%
(p = 0.359), 71 and 64% (p = 0.458), and 62 and
64% (p = 0.843). Patients in the Baerveldt group
were more likely to develop early postoperative
hypotony-related complications and failure,
whereas patients in the AGV group were more
likely to be on additional glaucoma medications
(starting at 18 months post-surgery) and to
develop later failure. These results should be
interpreted cautiously, considering the retro-
spective nature of the study and the absence of
patient matching at baseline. Patients in the
AGV group were older at baseline (69.2 vs.
62.3 years; p = 0.032), were more likely to have
a diagnosis of glaucoma associated with
inflammation (20.8% vs. 4.3%, p\0.01) and
had a higher pre-operative mean IOP (38.5 vs.
34.6 mmHg; p = 0.032).
The Ahmed versus Baerveldt study (AVB
study) was a prospective, multicenter, random-
ized clinical trial comparing AGV (model FP7)
and Baerveldt 350-mm2 implants in patients
affected by refractory glaucoma [53]. Surgical
procedures were standardized in all the centers
involved in the study. No manipulation to limit
filtration was performed in the AGV group,
while a releasable intraluminal nylon cord or a
polyglactin ligature suture was placed in the
Baerveldt devices that were implanted. Patients
were scheduled to be followed-up until 5 years
and failure was prospectively defined as
uncontrolled IOP (IOP[18 or\5 mmHg or IOP
reduction from baseline\20% in two consecu-
tive visits at or after 3 months), additional
glaucoma surgery, or loss of light perception.
Between October 2005 and March 2009, 238
patients were randomized to AGV (n = 124) or
Baerveldt (n = 114) implantation. The mean
number of previous surgical procedures was the
same between the two groups. Overall, the
mean number of previous interventions was
1.7 ± 1.2, the most common being cataract
extraction (172 patients, 72%), trabeculectomy
(89 patients, 37%), pars-plana vitrectomy (34
patients, 14%) and penetrating keratoplasty (19
patients, 8%). Only 27 patients had no previous
surgery performed (11%) [53]. At 1-year fol-
low-up, failure had occurred in 51 patients
(43%) in the AGV group and 30 patients (28%)
in the Baerveldt group (p = 0.02) [54]. The
cumulative probability of failure was 43% in the
AGV group and 28% in the Baerveldt group
(p = 0.049). At 3-year follow-up, failure had
occurred in 63 patients (51%) in the AGV group
and 39 patients (34%) in the Baerveldt group
(p = 0.013) [55]. The cumulative probability of
failure at 3 years was 51% in the AGV group and
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34% in the Baerveldt group (p = 0.03). Regard-
ing the IOP, from month 1 onward, the Baer-
veldt group had lower IOP values than the AGV
group, which reached statistical significance at
the 12- and 18-month time-points (p\0.01,
Fig. 2a). Mean IOP at 3 years was
15.7 ± 4.8 mmHg in the AGV group and
14.4 ± 5.1 mmHg in the Baerveldt group.
Although both groups had similar complication
rates, the Baerveldt group experienced more
frequently hypotony-related vision-threatening
complications than the AGV group (6 vs. 0%,
p\0.01). The authors concluded that, although
both devices are effective in reducing IOP in
patients with refractory glaucoma, the Baerveldt
implant achieves success in a higher percentage
of cases, at the cost of a higher rate of
hypotony-related complications.
The Ahmed Baerveldt Comparison study
(ABC) was a randomized, multicenter, con-
trolled clinical trial designed to prospectively
compare the safety and efficacy of these two
commonly implanted GDIs [56]. A total of 276
patients were enrolled by 16 centers worldwide
between October 2006 and April 2008. Totals of
143 patients were randomized to AGV (model
FP7) and 133 to Baerveldt implantation
(350-mm2 plate). All operations were performed
by experienced surgeons using the same stan-
dardized technique. The tube of the Baerveldt
GDI was totally occluded in order to restrict AH
flow until encapsulation of the plate was
achieved. The primary outcome measure was
failure, defined as follows: (1) IOP[21 mmHg or
IOP reduction\20% from baseline in two con-
secutive visits (at least 3 months after surgery);
(2) IOP\5 mmHg in two consecutive visits (at
least 3 months after surgery); (3) additional
glaucoma surgery including the removal of the
implant; and (4) loss of light perception. Most
common diagnoses at baseline were POAG
(40%), NVG (29%), PACG (7%) and uveitic
glaucoma (7%). Forty-two percent of patients
had previously undergone trabeculectomy,
while 20% of patients had no incisional surgery
at enrollment. Results of the study were repor-
ted at 1, 3 and 5 years [57–59]. In the AGV
group, IOP was reduced from 31.2 ±
11.2 mmHg at baseline to 15.4 ± 5.5 and
14.3 ± 4.7 mmHg at 1-year and 3-year fol-
low-up, respectively [57, 58]. In the Baerveldt
group, IOP was reduced from 31.8 ±
12.5 mmHg at baseline to 13.2 ± 6.8 and
13.1 ± 4.5 mmHg at 1-year and 3-year fol-
low-up, respectively [57, 58]. At 5 years, after
censoring for patients who underwent addi-
tional surgery or loss of light perception, IOP
was reduced from 29.6 ± 10.1 at baseline to
14.7 ± 4.4 mmHg in the AGV group and from
28.3 ± 9.3 at baseline to 12.7 ± 4.5 mmHg in
the Baerveldt group [59]. The AGV group
achieved lower IOP at 1-day and 1-week visits;
however, mean IOP in the Baerveldt group was
approximately 1–2 mmHg lower thereafter,
except at the 2-year visit (Fig. 2b). The cumula-
tive probability of failure was 44.7% in the AGV
group and 39.4% in the Baerveldt group at
5 years (p = 0.65). While the total number of
Fig. 2 Mean intraocular pressure in the Ahmed versus Baerveldt Study (a) and in the Ahmed Baerveldt Comparison Study
(b)
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failures was similar, the reasons for failure were
different between groups. Failure due to
uncontrolled IOP or reoperation was recorded
in 46 eyes of the AGV group and in 25 eyes of
the Baerveldt group (p\001). Only 11 eyes
experienced persistent hypotony or loss of light
perception in the AGV group, compared to 22
eyes in the Baerveldt group. No difference in the
rate of complications was found at 5 years [60],
with late complications developing in 56
patients in the AGV group and in 67 patients in
the Baerveldt group (p = 0.082). However, tube
occlusion (p = 0.037) and phthisis bulbi
(p = 0.037) occurred more frequently in the
Baerveldt group. Other complications resulting
in reoperation or vision loss were also more
common in the Baerveldt group (p = 0.034).
A recent meta-analysis by Wang et al. com-
pared the efficacyand safetyofAGVandBaerveldt
GDIs in patients with glaucoma [61]. Ten con-
trolled clinical trials (1048 eyes) were included in
this meta-analysis, involving 2 randomized clini-
cal trials and 8 retrospective comparative studies.
Short-term and long-term results were analyzed
separately. Definition of success was consistent
with the original studies, and a criterion of IOP
\21 mmHg was adopted. Over the short term
(714 eyes), the success rate was 78.6% and 79.7%
(OR 0.97, p = 0.90) for the AGV and the Baerveldt
groups, respectively, while over the long term
(835 eyes), the success rate was 59.2 and 68.4%
(OR 0.73, p = 0.04) for the AGV and the Baerveldt
groups, respectively. The AGV group had higher
IOP values than theBaerveldt group bothover the
short term (6 studies, 685 eyes, weighted mean
difference: 2.12 mmHg; 95% CI 0.72–3.52;
p\0.05) and the long term (7 studies, 659 eyes,
weighted mean difference: 1.85 mmHg; 95% CI
0.43–3.28; p = 0.01). However, eyes in the AGV
group experienced overall fewer complications
(OR 0.67; 95% CI 0.50–0.90; p\0.01), and espe-
cially fewer serious complications (OR 0.57; 95%
CI 0.36–0.91, p = 0.02).
Ahmed Glaucoma Valve Versus Molteno
and Krupin Implant
In an earlier study, Ayyala et al. compared the
efficacy of the double-plate Molteno GDI versus
the efficacy of the AGV [62]. In their retrospec-
tive, case–control study, 60 advanced glaucoma
patients matched for age, diagnosis, and previ-
ous surgeries underwent Molteno GDI (30
patients) or AGV implantation (30 patients).
Minimum follow-up was 6 months and success
was defined as follows: (1) IOP \22 and
[4 mmHg; (2) a decrease of no more than 2
lines in visual acuity; and (3) no additional
surgery to control IOP. At the 12- and
24-months follow-up, there was no difference in
the rate of success between the two groups (73
and 56% for the Molteno group and 60 and 50%
for the AGV group, at 12 and 24 months,
respectively, p = 0.72). Nevertheless, IOP was
significantly lower in patients implanted with
the Molteno GDI at both time-points. At 12 and
24 months, mean IOP was 13.36 ± 5.2 and
13.3 ± 5.1 mmHg in the Molteno group, and
16.7 ± 5.6 and 19 ± 5.8 in the AGV group
(p = 0.026 and p\0.01 for the comparisons at
12 and 24 months, respectively).
The efficacy of the AGV and the single-plate
Molteno GDI were compared in patients with
NVG in a study by Yalvac et al. (65 patients, 38
with AGV and 27 with Molteno GDI) [20].
Patients were matched for age, pre-operative
IOP, gender and follow-up. Surgical success was
defined as an IOP\22 and[5 mmHg, without
additional glaucoma surgery and no loss of light
perception. Patients using topical medications
for IOP control were not considered failures.
The overall success rates of the AGV were 63.2%
at 1 year, 56.1% at 2 years, 43.2% at 3 years,
37.8% at 4 years and 25.2% at 5 years. The suc-
cess rates of the Molteno GDI were 37%, 29.6%,
29.6%, 29.6% and 29.6%, respectively at the 1-,
2-, 3-, 4- and 5-year follow-ups. Although suc-
cess rates were always higher in the AGV group,
the log-rank test indicated no significant dif-
ference between survival curves (p = 0.141).
Patients implanted with the Molteno GDI had
more complications, especially hypotony-re-
lated, in the early postoperative phase. Chor-
oidal effusion was encountered in 5 eyes
(18.5%) in the Molteno group and 2 eyes (5.3%)
in the AGV group, shallow anterior chamber
was seen in 4 eyes (14.8%) in the Molteno group
and 2 eyes (5.3%) in the AGV group, and 1 case
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of suprachoroidal hemorrhage was observed in
the Molteno group (3.7%).
In a prospective, randomized, multicenter
study with a follow-up of 2 years, Nassiri et al.
compared the efficacy of the AGV (FP7 model)
and the Molteno GDI in a series of patients with
refractory glaucoma [63]. The study included 46
eyes randomized to AGV and 46 eyes random-
ized to Molteno GDI implantation. Treatment
success was defined as IOP between 6 and
21 mmHg, while failure was defined as IOP
[21 mmHg on maximally tolerated medical
therapy or IOP\6 mmHg on 2 consecutive vis-
its. Phthisis bulbi, loss of light perception, dev-
astating complications or reoperation were
considered failures. Cumulative probabilities of
success at 1 and 2 years were 88% and 82% in
the AGV group and 93% and 84% in the Mol-
teno group (log-rank test, p = 0.65). While IOP
was significantly lower in the AGV group com-
pared to the Molteno group at postoperative
day 1 and week 1, the Molteno group had sig-
nificantly lower pressures thereafter, up to
24 months. Complication rates were compara-
ble in the two groups and no case of persistent
hypotony or devastating complication was
encountered.
The efficacy and safety of the double-plate
Molteno, the Krupin implant and the AGV were
compared in a retrospective study by Taglia
et al. [64]. A total of 27 Molteno, 13 Krupin and
13 AGV implantations were included in this
study. The patients were matched for age and
diagnosis at baseline. However, patients in the
AGV group had higher IOP and used more
glaucoma medications than the other groups at
baseline. Two criteria of success were adopted:
(1) IOP[6 and\15 mmHg 3 months after sur-
gery (medications permitted) without addi-
tional filtration surgery and without tube
removal; and (2) IOP [6 and \21 mmHg
3 months after surgery (medications not per-
mitted) without additional filtration surgery
and without tube removal. The Molteno group
was significantly more likely than the AGV
group to satisfy the first criterion of success
(p\0.01, log-rank test), while a similar but
statistically non-significant tendency was
observed with the second criterion of success.
After 1 year, success rates according to the first
and the second criterion were, respectively, 80%
and 57% for the Molteno group, 39% and 46%
for the Krupin group and 35% and 25% for the
AGV group. None of the patients in the AGV
group had complications requiring reinterven-
tion. Thirteen of 27 patients (48%) in the Mol-
teno group required additional surgery, in most
cases during the first 3 months of follow-up (11
of 13 patients). Complications requiring re-in-
tervention were generally related to hypotony
despite the temporary ligation of the tube.
Seven of 13 patients (54%) in the Krupin group
had complications requiring re-intervention; 5
of these complications were hypotony-related.
The results of this report should be interpreted
with caution due to the small sample size and
the retrospective nature of the study.
Ahmed Glaucoma Valve Versus
Cyclodestructive Interventions
Cyclodestructive procedures have traditionally
been reserved for eyes with refractory glaucoma
and limited visual potential [65–68]. Immediate
and late complications of these procedures
include pain, visual acuity reduction, corneal
edema, persistent hypotony and phthisis bulbi
[69, 70]. An endoscopic technique which allows
direct visualization and laser treatment of the
ciliary body has been described [71]. Such an
endoscopic cyclophotocoagulation (ECP) device
combines a laser source, an endoscope, and an
illumination beam in the same probe
[68, 70, 72]. The technique appears promising
in terms of efficacy and safety [68, 70, 73].
In a study by Yildirim et al., 66 patients with
NVG and visual acuity of hand motion or worse
were randomized to AGV or transcleral diode
cyclophotocoagulation [69]. A minimum
24-month follow-upwas available for 58 of the 66
patients. Success was defined as an IOP\21 and
[5 mmHg without additional glaucoma surgery
and without loss of light perception. Post-opera-
tivemedicationswere allowedandnot considered
a failure. Preoperative IOPwas 43.4± 11.9 mmHg
in the cyclophotocoagulation group and
43.3± 7.4 mmHg in the AGV group (p[0.05). At
24 months, the IOPdecreased to18.72± 13.5and
22.88 ± 7.3 mmHg in the transcleral
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cyclophotocoagulation and AGV groups, respec-
tively (p[0.05). Success rates at 24 months were
similar in the two groups (61.18% and 59.26% for
the cyclophotocoagulation and AGV groups,
p[0.05). Themost frequent complications in the
cyclodestructive group were anterior segment
inflammation (5 eyes, 20%), neurotrophic kerati-
tis (2 eyes, 8%) andhypotony (3 eyes, 12%). In the
AGV group, hyphema was encountered in 5 eyes
(15%) and tube occlusion in 3 eyes (9%). No dev-
astating complications were noted in either
group.
The safety and efficacy of ECP through the pars
plana versus AGVwere compared in a prospective
study by Lima et al. [74]. Sixty-eight patients were
randomized to ECP (n = 34) or AGV implantation
(n = 34). To be eligible for inclusion patients had
to be pseudophakic with IOP C35 mmHg on
maximum tolerated medical therapy, have
undergone at least 1 previous trabeculectomy,
and have visual acuity better than light percep-
tion. Success was defined as IOP [6 and
\21 mmHg at 24 months with or without medi-
cations. Preoperative IOP was 41.32± 2.03
mmHg in the AGV group and 41.61± 3.42 in the
ECP group. At the 24-month follow-up, the IOP
was reduced to 14.73 ± 6.44 and 14.07 ± 7.21 in
the AGV and ECP groups, respectively (p = 0.07).
Success at 24 months was similar in the two
groups: 70.58% in the AGV group and 73.52% in
the ECP group (p = 0.5). Interestingly, eyes in the
AGVgrouphadagreater incidenceofvisual acuity
decline at 24 months. In the AGV group, a higher
rate of complicationswas encountered, including
choroidal detachment (17.64%) and shallow
anterior chamber (17.64%). It should be noted
that, in this study, laser treatment was performed
along the full length of the ciliary processes and
the anterior third of the pars plana over 210. This
rather extensive coagulationmayhave accounted
for the favorable ECP results. Further studies with
more patients and longer follow-up are needed to
clarify the role of ECP in the treatment of patients
with refractory glaucoma.
CONCLUSION
The role of GDIs has been traditionally limited
to patients with refractory glaucoma and
patients with high risk of failure after standard
filtering surgeries. The existing evidence seems
to suggest that AGV might have a more favor-
able safety profile when compared to non-
valved GDIs [20, 51, 52, 54, 55, 60, 61, 64]. On
the other hand, non-valved GDIs seem to
achieve lower pressures than the AGV
[54, 55, 57–59, 62–64]. AGV is a useful surgical
choice and represents a reasonable compromise
between efficacy and potential surgery-related
complications. Due to its safety profile, AGV
may be considered as the initial surgery in those
glaucomas that are more prone to failure after
standard filtering procedures. However, even in
these cases, the risk–benefit ratio has to be
carefully weighted and discussed with the
patient. In conclusion, the existing literature
suggests that the currently available AGV is
probably the GDI that offers the most favorable
risk-efficacy profile.
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